Low erythropoietin plasma levels during exacerbations of COPD

Respiration

Volumn 80, Issue 3, 2010, Pages 190-197

  Sala, Ernest ^a,b,c   Balaguer, Catalina ^a,c   Villena, Cristina ^c   Ríos, Angel ^b   Noguera, Aina ^a,b,c   Núñez, Belén ^a,b,c   Agustí, Alvar ^b,d  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b CIMERA ^*  (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chronic bronchitis; Emphysema; Hemoglobin

Indexed keywords

AMOXICILLIN; C REACTIVE PROTEIN; CLAVULANIC ACID; CYTOKINE; ERYTHROPOIETIN; FENOTEROL; INTERLEUKIN 1; IPRATROPIUM BROMIDE; LEVOFLOXACIN; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

AGED; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; GENE EXPRESSION; HORMONE BLOOD LEVEL; HUMAN; IN VITRO STUDY; INFORMED CONSENT; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; OXYGEN SATURATION; OXYGEN THERAPY; PATIENT INFORMATION; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SMOKING; SPIROMETRY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; C-REACTIVE PROTEIN; ERYTHROPOIETIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 77955561330     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264604     Document Type: Article

References (46)

1. Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 4 49-4 89.
2. Anagnostou A, Lee ES, Kessimian N, Levin-son R, Steiner M: Erythropoietin has a mito-genic and positive chemotactic effect on en-dothelial cells. Proc Natl Acad Sci USA 1990; 87:5978-5982.
3. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML: Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999; 126: 3597-3605.
4. Ogilvie M, Yu X, Nicolas-Metral V, et al: Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 2000; 275:39754-39761.
5. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R: Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998; 273: 25381-25387.
6. Heeschen C, Aicher A, Lehmann R, et al: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102:1340-1346.
7. Pelletier L, Regnard J, Fellmann D, Char-bord P: An in vitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokines. Lab Invest 2000; 80:501-511.
8. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH: Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64: 326-333.
9. La FK, Reimann C, Jelkmann W, Hellwig-Burgel T: Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J 2002; 16:1811-1813.
10. Celli BR, MacNee W, Agusti AG, et al: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J 2004; 23: 932-946.
11. Celli B: ERS/ATS COPD guidelines: novel aspects. Diagnosis and staging. Eur Respir J 20 03; 24: 23A.
12. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X: Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:347-360.
13. Wouters EF, Creutzberg EC, Schols AM: Systemic effects in COPD. Chest 2002; 121(5 suppl):127S-130S.
14. Van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008; 75: 224-238.
15. Malo O, Sauleda J, Busquets X, Miralles C, Agusti AG, Noguera A: Inflamación sistémi-ca durante las agudizaciones De La enferme-dad pulmonar obstructiva crónica. Arch Bronconeumol 2002; 38:172-176.
16. Dentener MA, Creutzberg EC, Schols AM, et al: Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56:721-726.
17. Drost EM, Skwarski KM, Sauleda J, et al: Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60:293-300.
18. Wedzicha JA, Seemungal TA, MacCallum PK, et al: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-215.
19. Zeng M, Wen Y, Liu LY, Wang H, Guan KP, Huang X: Role of TNF-a, sTNF-R55 and sTNF-R75 in inflammation of acute exacerbations of chronic obstructive pulmonary disease. Respiration 2009;78:399-403.
20. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD: Anemia and inflammation in COPD. Chest 2005; 127: 825-829.
21. Rabe KF, Hurd S, Anzueto A, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
22. Lightfoot BO, Mulloy LL, Jagadeesan M, Ahmed S, Balachandran S: ACEi induced attenuation of platelet TIMP-1 production in renal allograft recipients: possible impact on erythropoiesis. Transplant Proc 2002; 34: 1806-1807.
23. Ponce S, Orive G, Hernández RM, Gascón AR, Canals JM, Muñoz MT, Pedraz JL: In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL micro-capsules. J Control Release 2006; 116 : 28-34.
24. World Health Organization: Nutritional anemias: report of a WHO scientific group. Who Tech Report Ser 1968; 405.
25. American Thoracic Society Official Statement: Standardization of Spirometry 1994 Update. Am J Respir Crit Care Med 1995; 152:1107-1136.
26. Roca J, Sanchis J, Agustí-Vidal A, et al: Spi-rometric reference values for a Mediterranean population. Bull Eur Physiopathol Respir 1986; 22: 217-2 2 4.
27. Casale R, Pasqualetti P: Diurnal rhythm of serum erythropoietin circulating levels in chronic obstructive pulmonary disease. Panminerva Med 1997; 39:183-185.
28. Fitzpatrick MF, Mackay T, Whyte KF, et al: Nocturnal desaturation and serum erythro-poietin: a study in patients with chronic obstructive pulmonary disease and in normal subjects. Clin Sci (Lond) 1993; 84: 31 9-3 2 4.
29. Tassiopoulos S, Kontos A, Konstantopoulos K, et al: Erythropoietic response to hypoxae-mia in diffuse idiopathic pulmonary fibro-sis, as opposed to chronic obstructive pulmonary disease. Respir Med 2001; 95: 471-475.
30. Guidet B, Offenstadt G, Boffa G, et al: Poly-cythemia in chronic obstructive pulmonary disease: a study of serum and urine erythro-poietin and medullary erythroid progenitors. Chest 1987; 92:867-870.
31. Pavlisa G, Vrbanic V, Kusec V, Jaksic B: Erythropoietin response after correction of severe hypoxaemia due to acute respiratory failure in chronic obstructive pulmonary disease patients. Clin Sci (Lond) 2004; 106: 43-51.
32. Valipour A, Schreder M, Wolzt M, et al: Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008; 115 : 225-232.
33. Braczkowski R, Romanawsky W, Danikie-wicz A, Muc-Wierzgon M, Blazelonis A, Zubelewicz B: Decrease of erythropoietin level by human recombinant tumour necrosis factor alpha (hrec TNFalpha) in patients with advanced cancer. J Biol Regul Homeost Agents 2001; 15:366-369.
34. Ebrahim O, Folb PI, Robson SC, Jacobs P: Blunted erythropoietin response to anaemia in tuberculosis. Eur J Haematol 1995; 55: 251-254.
35. Jelkmann W: Proinflammatory cytokines lowering erythropoietin production. J Inter-feron Cy tokine Res 1998; 18 : 555-559.
36. Stockmann C, Fandrey J: Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 20 06; 33: 968-979.
37. Fandrey J: Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004; 286:R977-R988.
38. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B: Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29:923-929.
39. Sin DD, Man SF: Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 20 05; 2: 8-11.
40. Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: role of comorbidi-ties. Eur Respir J 2006; 28: 12 4 5-1257.
41. Nakano M, Satoh K, Fukumoto Y, et al: Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007; 100:662-669.
42. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000; 106:1311-1319.
43. Lim GB, Dodic M, Earnest L, Jeyaseelan K, Wintour EM: Regulation of erythropoietin gene expression in fetal sheep by glucocorti-coids. Endocrinology 1996; 137:1658-1663.
44. Leng HM, Kidson SH, Keraan MM, Randall GW, Folb PI: Cytokine-mediated inhibition of erythropoietin synthesis by dexametha-sone. J Pharm Pharmacol 1996; 48:971-974.
45. Amylon MD, Perrine SP, Glader BE: Predni-sone stimulation of erythropoiesis in leuke-mic children during remission. Am J Hema-tol 1986; 23: 17 9-181.
46. Casale R, Pasqualetti P: Diurnal rhythm of serum erythropoietin circulating levels in chronic obstructive pulmonary disease. Panminerva Med 1997; 39:183-185.